Adicet Bio (ACET) News Today $0.88 -0.03 (-3.20%) Closing price 04:00 PM EasternExtended Trading$0.89 +0.01 (+0.68%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Adicet Bio's (ACET) Buy Rating Reiterated at GuggenheimMarch 24 at 1:41 AM | americanbankingnews.comAdicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23 at 10:26 AM | insidermonkey.comAdicet Bio (NASDAQ:ACET) Receives "Buy" Rating from GuggenheimGuggenheim restated a "buy" rating and issued a $7.00 price target on shares of Adicet Bio in a report on Friday.March 22 at 10:11 AM | marketbeat.comShort Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 16.9%Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 3,140,000 shares, a decrease of 16.9% from the February 13th total of 3,780,000 shares. Based on an average trading volume of 834,000 shares, the days-to-cover ratio is currently 3.8 days. Approximately 4.7% of the company's stock are sold short.March 18, 2025 | marketbeat.comAdicet Bio’s SWOT analysis: gamma-delta T cell stock faces pivotal yearMarch 14, 2025 | investing.comRegeneron Pharmaceuticals Inc. Makes New $931,000 Investment in Adicet Bio, Inc. (NASDAQ:ACET)Regeneron Pharmaceuticals Inc. purchased a new stake in Adicet Bio, Inc. (NASDAQ:ACET - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 968,183 shares of the company's stock, valued at approximatMarch 11, 2025 | marketbeat.comAdicet Bio (ACET) Expected to Announce Earnings on TuesdayAdicet Bio (NASDAQ:ACET) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comTruist Financial Reaffirms Their Buy Rating on Adicet Bio (ACET)March 10, 2025 | markets.businessinsider.comAdicet Bio (NASDAQ:ACET) Receives "Neutral" Rating from HC WainwrightHC Wainwright reiterated a "neutral" rating on shares of Adicet Bio in a research note on Friday.March 8, 2025 | marketbeat.comAdicet Bio (NASDAQ:ACET) Issues Earnings ResultsAdicet Bio (NASDAQ:ACET - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.05.March 7, 2025 | marketbeat.comAdicet Bio reports Q4 EPS (32c), consensus (35c)March 6, 2025 | markets.businessinsider.comAdicet Bio files $250M mixed securities shelfMarch 6, 2025 | markets.businessinsider.comAdicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company ProgressMarch 6, 2025 | businesswire.comAdicet Bio, Inc. (NASDAQ:ACET) Short Interest UpdateAdicet Bio, Inc. (NASDAQ:ACET - Get Free Report) was the target of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 3,780,000 shares, an increase of 27.3% from the January 31st total of 2,970,000 shares. Based on an average daily volume of 905,100 shares, the days-to-cover ratio is presently 4.2 days.March 5, 2025 | marketbeat.comAdicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific MeetingMarch 3, 2025 | finance.yahoo.comAdicet Bio, Inc. (NASDAQ:ACET) Given Average Rating of "Moderate Buy" by AnalystsShares of Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) have earned an average rating of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and three have assigned a buy ratingMarch 3, 2025 | marketbeat.comAdicet Bio's (ACET) "Neutral" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "neutral" rating on shares of Adicet Bio in a research note on Thursday.February 28, 2025 | marketbeat.comAdicet Bio shares rise on FDA Fast Track Designation for ADI-001February 27, 2025 | finance.yahoo.comAdicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)February 27, 2025 | businesswire.comAdicet Bio granted fast track designation for ADI-001 by FDAFebruary 6, 2025 | markets.businessinsider.comAdicet Bio, Inc. (NASDAQ:ACET) Given Consensus Rating of "Moderate Buy" by BrokeragesAdicet Bio, Inc. (NASDAQ:ACET - Get Free Report) has received a consensus rating of "Moderate Buy" from the four analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and three have given a buy recommeFebruary 6, 2025 | marketbeat.comAdicet Bio's (ACET) Market Perform Rating Reaffirmed at JMP SecuritiesJMP Securities reissued a "market perform" rating on shares of Adicet Bio in a research report on Thursday.February 6, 2025 | marketbeat.comAdicet Bio's (ACET) "Neutral" Rating Reiterated at HC WainwrightHC Wainwright reissued a "neutral" rating on shares of Adicet Bio in a report on Wednesday.February 5, 2025 | marketbeat.comAdicet Bio Gets Fast Track Designation For ADI-001 In Refractory Systemic Lupus ErythematosusFebruary 5, 2025 | markets.businessinsider.comAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)January 31, 2025 | businesswire.comAdicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | finance.yahoo.comAdicet Bio Provides Corporate Update and Highlights Expected 2025 MilestonesJanuary 8, 2025 | businesswire.comAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)December 31, 2024 | businesswire.comAdicet Bio, Inc. (NASDAQ:ACET) Sees Large Increase in Short InterestAdicet Bio, Inc. (NASDAQ:ACET - Get Free Report) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 3,350,000 shares, a growth of 12.0% from the November 30th total of 2,990,000 shares. Based on an average daily volume of 598,300 shares, the days-to-cover ratio is presently 5.6 days.December 30, 2024 | marketbeat.comAdicet Bio (NASDAQ:ACET) Stock Passes Below 200-Day Moving Average - Time to Sell?Adicet Bio (NASDAQ:ACET) Stock Crosses Below 200-Day Moving Average - Here's WhyDecember 28, 2024 | marketbeat.comH.C. Wainwright Remains a Hold on Adicet Bio (ACET)December 23, 2024 | markets.businessinsider.comAdicet Bio says 1st patient dosed in Phase1 trial of ADI-270 to treat ccRCCDecember 20, 2024 | markets.businessinsider.comAdicet Bio's (ACET) Neutral Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "neutral" rating on shares of Adicet Bio in a report on Thursday.December 19, 2024 | marketbeat.comAdicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell CarcinomaDecember 19, 2024 | finance.yahoo.comAdicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal yearDecember 19, 2024 | uk.investing.comAdicet Bio Appoints Julie Maltzman As CMODecember 18, 2024 | markets.businessinsider.comShort Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 18.1%Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) was the recipient of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 2,990,000 shares, a decrease of 18.1% from the November 15th total of 3,650,000 shares. Based on an average daily trading volume, of 576,900 shares, the days-to-cover ratio is currently 5.2 days.December 14, 2024 | marketbeat.comShort Interest in Adicet Bio, Inc. (NASDAQ:ACET) Expands By 6.1%Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 3,650,000 shares, an increase of 6.1% from the October 31st total of 3,440,000 shares. Based on an average daily trading volume, of 529,000 shares, the short-interest ratio is currently 6.9 days.December 3, 2024 | marketbeat.comAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)November 29, 2024 | businesswire.comAdicet Bio Reports Q3 2024 Results and Clinical ProgressNovember 22, 2024 | markets.businessinsider.comAdicet Bio begins lupus nephritis trial, eyes other diseasesNovember 20, 2024 | uk.investing.comAdicet Bio begins trial for innovative cancer therapyNovember 20, 2024 | investing.comAdicet Bio opens enrollment for ADI-270 phase 1 clinical trial in ccRCCNovember 19, 2024 | markets.businessinsider.comAdicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell CarcinomaNovember 18, 2024 | finance.yahoo.comAdicet Bio:1st patient dosed in trial evaluating ADI-001 in autoimmune diseasesNovember 18, 2024 | markets.businessinsider.comAdicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC WainwrightHC Wainwright restated a "neutral" rating on shares of Adicet Bio in a research report on Monday.November 18, 2024 | marketbeat.comAdicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024November 16, 2024 | businesswire.comAdicet Bio IncNovember 15, 2024 | money.usnews.comHC Wainwright Decreases Earnings Estimates for Adicet BioAdicet Bio, Inc. (NASDAQ:ACET - Free Report) - HC Wainwright decreased their FY2024 EPS estimates for shares of Adicet Bio in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst E. White now forecasts that the company will earn ($1.39) per share for the year, downNovember 11, 2024 | marketbeat.comAdicet Bio: Hold Rating Amid Financial Stability and Anticipated Clinical DataNovember 8, 2024 | markets.businessinsider.com Remove Ads Get Adicet Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter. Email Address ACET Media Mentions By Week ACET Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACET News Sentiment▼0.820.68▲Average Medical News Sentiment ACET News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACET Articles This Week▼52▲ACET Articles Average Week Remove Ads Get Adicet Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GWW News FAST News URI News WSO News AIT News WCC News BECN News GATX News AL News MSM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACET) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adicet Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
